The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
The successful treatment of certain autoimmune conditions with the humanized anti–IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Introduction

Inflammation is not a disease but a consequence of disease and is the body’s defense against infection or injury. When effective, the inflammatory response ensures successful resolution of the condition and forms part of the normal healing process. Regulation of this response is centrally controlled by cytokine-driven communication, which governs both innate and adaptive immunity. In more progressive chronic inflammatory diseases, the natural course of inflammation is lost, resulting in disease progression instead of protection. The successful treatment of inflammatory conditions with biologics that block cytokine activity indicates that imbalanced proinflammatory and antiinflammatory cytokine responses contribute to the induction of autoimmunity, chronic inflammation, and associated tissue damage (1, 2). Although these drugs have provided considerable clinical benefit, we have yet to fully understand how the cytokine network becomes distorted to drive chronic inflammation rather than competent host defense (2).

Preclinical models have emphasized the involvement of numerous cytokines in the pathology of various inflammatory diseases and cancers. As a consequence, cytokines have become major therapeutic targets for clinical intervention. For example, mAbs that target TNF-α are now the standard treatment for patients with chronic inflammatory arthritis, and alternative therapies, which target other cytokines, are also emerging in routine clinical practice (1, 2). These agents work by either targeting the cytokine directly or by inhibiting cytokine binding to their specific receptors on the surface of cells. In this regard, they are designed to prevent cytokine signaling within cells. This fundamental mode of action has also fueled renewed excitement about the possibility of blocking certain intracellular cytokine signaling pathways with small molecule inhibitors. The challenge is to identify which cytokine or signaling molecule represents the most appropriate intervention target for a particular patient group. In this regard, a candidate pharmaceutical needs to block a sufficiently broad number of pathological processes associated with the disease but should also confer a minimal impact on safety concerns, such as infection incidence, cardiovascular risk, and malignancy.

Frontline therapies for chronic inflammation

Biologics, including the anti–TNF-α agents (e.g., the neutralizing anti–TNF-α antibodies infliximab, adalimumab, golimumab, and certolizumab or the soluble TNF-R2 Fc-fusion protein etanercept), are broadly used drugs that reduce inflammation. The clinical success of these agents has led to a significant research interest in the control of TNF-α processing and signaling (1). Less attention has been given to cytokines that signal through the JAK/STAT pathway (3). However, cytokines that signal via this pathway (e.g., IFN-γ, GM-CSF, IL-6, IL-10, IL-15, IL-23) have become increasingly linked with the pathogenesis of chronic inflammatory diseases and cancers (2, 4). Biologics are now emerging that target these cytokines (e.g., IL-6R blockade by tocilizumab), and selective small molecule JAK inhibitors (e.g., tofacitinib, ruxolitinib) also show favorable phase IIa efficacy in patients with rheumatoid arthritis (5–8). With this rise in the number of biological interventions entering the clinical arena, it has become increasingly important to understand how specific cytokine pathways interface with the inflammatory process to affect disease outcome. This represents a major challenge for both basic and clinical researchers alike. Throughout this Review, we will assess the merits of targeting cytokines that signal via the universal signal-transducing β-receptor subunit for all IL-6 related cytokines, glycoprotein 130 (gp130).

The involvement of gp130-related cytokines in homeostasis and disease

gp130 (also known as CD130) is expressed in almost all organs, including heart, kidney, spleen, liver, lung, placenta, and brain, and targeted deletion of the gp130 gene in mice results in embryonic lethality at day 12.5 (9). Histological assessments showed that these animals display hypoplastic ventricular myocardium and greatly reduced numbers of hematopoietic progenitors in the liver and T cells in the thymus (9). These data demonstrate that gp130 plays a fundamental role in development, hematopoiesis, cell survival, and growth.

Although initially identified as the β subunit of the IL-6R complex, gp130 also transmits signals for IL-11, IL-27, oncostatin-M

Conflict of interest: Stefan Rose-John is an inventor on the patent describing the function of sgp130Fc. He is also a shareholder of the CONARIS Research Institute (Kiel, Germany), which is commercially developing sgp130Fc as a therapy for inflammatory diseases. Simon A. Jones has a consultancy agreement with Roche Pharmaceuticals and advises research relating to the clinical introduction of Actemra/RoActemra.

Citation for this article: J Clin Invest. 2011;121(9):3375–3383. doi:10.1172/JCI57158.
(OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), leukemia inhibitory factor (LIF), and the cardiotrophin-like cytokine (CLC) (10–17) (herein referred to as gp130-related cytokines) (Figure 1). Many of these factors elicit similar activities, and the phenotypic characteristics of mice lacking IL-6, IL-11, LIF, or CNTF are less severe than the apparent pleiotropic properties of these mediators would suggest (13, 15). In this regard, gp130-related cytokines display not only a degree of functional redundancy but also specialization, and some of these functions are not necessary for embryo development.

Studies of mice deficient in gp130-related cytokines demonstrate that these individual family members perform central roles in development and tissue homeostasis. For instance, CNTF, LIF, and CLC act as neurotrophic factors important for the survival and development of motor neurons (11, 12). Similarly, OSM, LIF, IL-6, and IL-11 affect multiple hematopoietic processes (including megakaryocyte maturation) and control liver regeneration and hepatocyte proliferation. In some instances these cytokines elicit defined aspects of the same biological process. For example, female IL-11 receptor-α-deficient (IL-11R–deficient) mice are infertile due to defective decidualization (18), while expression of LIF in maternal endometrial glands is required for early embryogenesis and embryo implantation (19). These examples help to collectively build the argument that certain gp130-related cytokines govern cellular differentiation and survival in many different organ/tissue/cellular compartments (e.g., LIF, IL-6), while others display more restricted activities affecting a single organ, such as the role of CT-1 in the heart or CNTF and CLC in neurons.

In addition to the control of homeostatic processes, gp130-related cytokines play integral roles in infection, immunity, and inflammation. In particular, IL-6-deficient (IL-6KO) mice are viable but show numerous immunological defects (15). Experimental models show that IL-6KO mice resist the induction of a number of autoimmune conditions (reviewed in ref. 20), although this is not true for animals with defective production of TNF-α, a cytokine that frequently cooperates with IL-6 (21–23). For example, IL-6KO mice show limited susceptibility to antigen-induced arthritis (24), collagen-induced arthritis (25, 26), experimental autoimmune encephalomyelitis (27), multicentric Castleman disease (28), and pristane-induced plasmacytomas (29). These early studies fueled interest in IL-6 as a therapeutic target for autoimmunity and led to the development of agents such as tocilizumab.

**Mechanisms of IL-6R signaling**

IL-6 is the archetypal member of the gp130-related cytokine family. IL-6 activates cells by first binding a nonsignaling α-receptor (IL-6R, also known as CD126), which, after dimerization with gp130, leads to activation of receptor-associated kinases (JAK1, JAK2, and Tyk2) within the cell. In turn these lead to phosphorylation of proximal tyrosine residues within the intracellular portion of gp130, and the subsequent control of STAT1 and STAT3 activity, and the Src homology region 2 domain-containing phosphatase 2 cascade (14).
Importantly, the IL-6R functions as both a membrane-bound protein, which is expressed by hepatocytes and certain inflammatory cells, and a soluble form (sIL-6R), which is readily detected in the circulation and at sites of inflammation (Figure 1). Throughout this Review, we will refer to IL-6 signaling through membrane-bound IL-6R as classical IL-6R signaling, and IL-6 trans-signaling will be used to describe activities elicited via sIL-6R (30–32).

Interestingly, although mice deficient in IL-6R (CD126-KO mice) display similar phenotypic characteristics to those of IL-6KO mice (33, 34), subtle differences in their functional behavior have been noted. For example, CD126-KO and IL-6KO mice show differences in wound healing (34). Similarly, hepatocyte-specific CD126-KO mice show a lower insulin sensitivity and glucose tolerance, which can be restored by TNF-α neutralization or Kupffer cell depletion (35). The mechanistic basis for these differences currently remains unclear.

In contrast to IL-6KO and CD126-KO strains, mice deficient in related cytokine signaling pathways do not display a similar resistance to autoimmunity. For example in models of arthritis, IL-11R–deficient mice and OSM receptor-β-deficient (OSMRKO) mice develop disease severity comparable to that of wild-type controls (36). Interestingly, IL-27 suppresses development of collagen-induced arthritis and in human cells systems inhibits osteoclastogenesis (37, 38). Similarly, IL-11 regulates many antiinflammatory activities in arthritis models (39, 40), although trials using recombinant IL-11 in patients with rheumatoid arthritis were suspended due to poor efficacy (41). Other gp130-related cytokines may, however, govern defined aspects of pathology, as is illustrated by the role of IL-11 and OSM in bone turnover (42). Indeed, IL-27α is largely confined to nonhematopoietic stromal cells, while IL-27Rxα is restricted to lymphocytes, monocytes, and osteoclasts (14, 55). Indeed, IL-27 often opposes the action of IL-6 and is the only member of the gp130-related cytokine family to predominantly signal via the latent transcription factor STAT1 instead of STAT3 (14, 55). In this context, IL-27 acts as a negative regulator of Th17 commitment, while the p28 subunit of IL-27 also antagonizes IL-6–mediated T cell responses (56–58). However, as described earlier, the critical difference between IL-6 and related cytokines is the existence of a natural sIL-6R, which in humans is generated through differential mRNA splicing but primarily through proteolytic cleavage and subsequent shedding of membrane-bound IL-6R (30, 59). The affinity of IL-6 for sIL-6R is comparable to that of the membrane-bound receptor (~1 nm), and sIL-6R is found at high concentrations in human serum and urine (60, 61). The function of sIL-6R is two fold. The formation of an IL-6/sIL-6R complex not only protects IL-6 and prolongs its circulating half-life (62), but also acts as an agonist capable of directly activating cells through membrane-bound gp130. This trans-signaling enables IL-6 to activate cells that inherently lack the α subunit for the IL-6R and would normally not respond to this cytokine (30, 63). Consequently, IL-6 trans-signaling may mimic or supplement the paracrine or autocrine activities of certain other gp130-activating cytokines (64). Moreover, since gp130 is ubiquitously expressed, the IL-6/sIL-6R complex can also stimulate cells that are nonresponsive to any other gp130-related cytokine (Figure 1). Although protein-engineering experiments with recombinant soluble receptors for CNTF and IL-11 have recapitulated this signaling mechanism in vitro, IL-6 remains the only example of a cytokine that in vivo uses both classical membrane-bound receptor signaling and trans-signaling through its soluble receptor (10, 63). The IL-6/sIL-6R complex therefore resembles a heterodimeric cytokine akin to either IL-12 (the IL-12p40 subunit shares 60% identity with sIL-6R) or IL-27 (14, 65). Consequently, those who implement therapeutic strategies need to consider the impact of blocking classical membrane-bound signaling and IL-6 trans-signaling (Figure 2). The anti-IL-6R antibody tocilizumab globally blocks IL-6 activities since it inhibits both modes of IL-6 signaling (66).

While research from our groups and others increasingly points toward roles for IL-6 trans-signaling in regulating processes localized to the site of disease, infection, or injury, less is known about the IL-6 control of homeostatic processes, such as fatigue, mood,
emphasizes the central physiological importance of IL-6 trans-signaling. It is not, however, clear why IL-6 uses two distinct modes of receptor signaling. As a soluble cytokine receptor, sIL-6R has been proven to prolong the signaling activity and circulating half-life of IL-6 (62). Indeed, for cells lacking IL-6R (but expressing gp130), IL-6 trans-signaling remains the only mechanism by which these cells respond to IL-6. sIL-6R levels are therefore rate limiting and prevent an inadvertent IL-6 activation of endothelial cells and fibroblasts. In cell types expressing membrane-bound IL-6R, the situation may be slightly more complex. Here the surface expression of gp130 is generally greater than that of IL-6R, and trans-signaling can amplify the IL-6 signal through increased gp130 engagement (62, 64). IL-6R is expressed at a higher level in CD4+ T cells than CD8+ T cells and is closely linked with the expression of CCR7 and CD62L in CD4+ T cells (i.e., naive or central memory T cell populations) (33). In contrast, effector cells from sites of inflammation lack IL-6R, and pan-TCR activation increases IL-6R shedding (33, 87, 88). Consequently, activated CD44hiCD62LloCD4+ T cells lose their capacity to respond to classical IL-6 activation (33), yet these cells still respond to IL-6 trans-signaling, which promotes the expression of antiapoptotic regulators, such as Bcl-2 and Bcl-xl (33, 87). However, IL-6 trans-signaling is unable to drive Th17 production in preactivated CD4+ T cells (33). Instead, IL-6 trans-signaling helps to maintain the effector characteristics of already precommitted Th17 cells (33). Although the mechanism for this response remains unclear, the level of IL-6R expression on T cells has been associated with changes in IL-6–mediated STAT1 but not STAT3 signaling (89). These data suggest an activation-induced alteration in IL-6 responsiveness. While these changes have been linked to the regulation of T cell apoptosis, it is conceivable that such alterations in STAT signaling may also influence the control of T cell commitment. Similar data were also observed in FoxP3 regulatory T cells, suggesting that classical IL-6-R signaling and IL-6 trans-signaling can orchestrate both similar and distinct T cell responses (33, 90, 91).

How does gp130 signaling drive disease?

The central signaling molecule activated by gp130 is the latent transcription factor STAT3, which is phosphorylated by JAK proteins constitutively bound to the cytoplasmic portion of gp130. STAT3-deficient animals are not viable after embryonic day 7.5, and conditional deletion of the STAT3 gene in bone marrow cells during hematopoiesis causes Crohn disease–like pathology, overt alterations in innate immune responses, enhanced NF-κB activity, and increased lethality at 4–6 weeks (92, 93). These studies demonstrate that STAT3 is an integral component of development, inflammation, and cancer (94).

The clinical efficacy of tocilizumab suggests that IL-6/STAT3 signaling actively contributes to the pathology of autoimmune disorders, including rheumatoid arthritis (2). Activated STAT3 is detected at high levels in diseased tissues such as synovial biopsies from patients with rheumatoid arthritis (3, 95). In models of arthritis, levels of activated STAT3 are rapidly increased after disease induction and localized within the synovial lining and CD3+ T cell clusters (54, 79). Indeed, STAT3 stimulation via IL-6/sIL-6R promotes synovial hyperplasia, joint erosion, chemokine-directed leukocyte recruitment, and the maintenance of effector cells within the inflamed joint (36, 54, 78, 79, 96, 97). To mechanistically link the control of disease processes with IL-6/STAT3 signaling, an increasing number of studies have used a gp130 knockin mouse.
model in which an amino acid substitution prevents feedback inhibition of the receptor, resulting in exaggerated STAT3 signaling (79, 98, 99). In these systems, monoallelic deletion of Stat3 led to a reduction in inflammation and overall pathogenesis (79). However, IL-6/STAT3 involvement has received the most attention in the field of tumor biology.

**Perspectives on cancer**

STAT3 activity often correlates with tumorogenesis and is associated with tumor growth, survival, angiogenesis, and metastatic processes, including epithelial-mesenchymal transition, degradation of extracellular matrix, and cell migration (100, 101). Each of these processes can be linked experimentally to gp130 signaling (4). For instance, in murine models of inflammation-induced colorectal cancer, STAT3-dependent tumorogenesis has been associated with both the local secretion of IL-6 (102, 103) and regulation of IL-6 trans-signaling (80, 83) within the tumor microenvironment. These studies have identified a link between IL-6 and tumor-associated inflammation. Indeed, STAT3 activation in an oncogenic K-Ras-driven pancreatic tumor model does not develop spontaneously but is instead regulated by IL-6 and sIL-6R from myeloid tumor infiltrating cells (84). Similarly, it was recently shown in a newly developed model of ulcerative colitis–associated colon cancer that IL-6 produced by M2-type macrophages via IL-6 trans-signaling is involved in tumorogenesis (104). Interestingly, IL-6 was responsible for the higher prevalence of liver cancer in male littermates in this model (105). Although many studies have identified IL-6 as a major tumor-associated cytokine, IL-11 might also contribute to inflammation-induced cancer, as suggested from a study on gp130 signaling in gastric cancer (106). These underlying themes are also evident in human cancers in which IL-6/STAT3 activity is associated with tumor progression and poor prognosis. For example, in hepatocellular adenoma, somatic mutations coding for constitutively activated gp130 have been detected (107), while elevated IL-6 levels in patients with breast, lung, and hematopoietic tumors correlate with poor clinical outcome (108, 109). Biomarkers of STAT3 activity also represent reliable diagnostic/prognostic factors for patients with colorectal neoplasia and non–small cell lung carcinoma (100, 110–112). Furthermore, ADAM17, which mediates the ectodomain shedding (and activation) of some EGFR ligands, Notch and IL-6R, is also upregulated in various cancers (113) and is considered a novel antitumor drug target (114).

**How can gp130 be blocked?**

In the early 1990s, IL-6 was recognized as a major growth factor in multiple myeloma, and since that time, elevations in circulating IL-6 and sIL-6R levels have been used as prognostic indicators (reviewed in ref. 59). These studies led to clinical trials with neutralizing anti–IL-6 antibodies, which showed good antitumor efficacy and a normalization of acute phase activity (115). However, antibody treatment led to massive systemic elevations (approaching mg quantities) in IL-6. Subsequent pharmacokinetic experiments revealed that antibody-associated IL-6 was not cleared from the circulation, leading to a reservoir of free IL-6 as concentrations reached the Kₚ of the antibody (116). To overcome such difficulties, targeting strategies were redirected toward blockade of IL-6R. This led to development of tocilizumab, which prevents binding of IL-6 to IL-6R (117). Patients treated with tocilizumab show only a mild accumulation of IL-6, due to blockade of IL-6R–dependent internalization, which regulates IL-6 clearance (118). The humanized antibody tocilizumab is now marketed as Actemra (RoActemra in the EU), which is approved for the treatment of rheumatoid arthritis in Europe and the US (Table 1). Other IL-6–directed neutralizing antibodies are in clinical development as antiinflammatory and anticancer therapeutics (52), and these include human-mouse chimeric and fully humanized antibodies to human IL-6 (Table 1). However, each of these agents globally inhibits IL-6 activities, without differentiating between classical and trans-signaling (Figure 2).

The ubiquitous cellular expression of gp130 suggests that IL-6 trans-signaling has the potential to stimulate all cell types within the body. As noted above, this may in part be regulated by sgp130 variants, which circulate at high levels in human sera and selectively antagonize IL-6 trans-signaling (32). This finding has opened up the possibility of using sgp130 as a therapeutic modality for the treatment of inflammation. sgp130 linked to the Fc portion of IgG (sgp130Fc; ref. 77) is currently in preclinical development and shows efficacy in animal models of inflammatory arthritis, peritonitis, inflammatory bowel disease, and colon cancer (8, 52, 71, 76, 78–80). These results suggest that during chronic disease progression, IL-6 trans-signaling primarily drives the proinflammatory activities of IL-6. However, it is important to note that IL-6 also governs certain antiinflammatory responses, including the resolution of innate immune responses, and the control of cytokine regulators, such as the soluble TNF receptor p55 and the IL-1 receptor antagonist (71, 119). The regulation of these activities may have important implications in the control of antimicrobial host defense and inflammation-associated tumor immunity (31, 71, 102). The challenge will be to determine whether sgp130Fc offers a true clinical advantage over more standard mAb therapies against IL-6 or IL-6R.

**Hurdles of gp130 blockade**

Due to the clinical successes of anti–TNF-α agents in treating inflammation, it is often difficult to promote the advantages of newer, alternative anti-cytokine–based biologic treatments. For example, the mechanism of action of tocilizumab is regularly compared with the mechanism of action of adalimumab or etanercept. However, not all patients respond to anti–TNF-α therapy, and approximately 45% of patients with inflammatory arthritis show poor response to treatment. Interestingly, a phase III trial in patients with rheumatoid arthritis failing anti–TNF-α therapy showed that certain individuals display increased responsiveness to tocilizumab (120, 121). Consequently, TNF-α and IL-6 may have unique roles in inflammatory arthritis. This does not fit with the traditional view that TNF-α is upstream of IL-6 in an inflammatory cytokine cascade. Such models probably do not reflect the complexity of the in vivo situation and were outlined prior to our increasing understanding of IL-6 trans-signaling. In support of this, it has been demonstrated that TNF-α does not induce IL-6R shedding (122). As alternative anti–IL-6–based modalities (Table 1) filter into the clinic, their efficacies will need to be distinguished from those of the anti–TNF-α blockers and tocilizumab. While these are challenging clinical considerations, a recent murine study of IL-6 involvement in sepsis provides an example of the type of thinking required. Using a cecal ligation and puncture sepsis model, the authors showed that global blockade of IL-6 by neutralizing antibodies was not beneficial, whereas selective inhibition of IL-6 trans-signaling resulted in increased animal survival (123). A possible explanation for these findings lies in the recent apprecia-
### Table 1
Targeting IL-6 in disease

<table>
<thead>
<tr>
<th>Targeting strategy</th>
<th>Compound</th>
<th>Company</th>
<th>Specificity</th>
<th>Disease</th>
<th>Phase</th>
<th>Clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Global IL-6 blockade</strong></td>
<td><strong>Tocilizumab</strong> (Actemra, RoActemra)</td>
<td>Chugai, Roche</td>
<td>Humanized IL-6R–specific mAb</td>
<td>Castleman disease</td>
<td>2005, Japan</td>
<td>Approved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Juvenile idiopathic arthritis</td>
<td>2008, Japan</td>
<td>Approved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Systemic-onset juvenile idiopathic arthritis</td>
<td>2008, Japan</td>
<td>Approved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rheumatoid arthritis</td>
<td>2009, EMEA; 2010, FDA</td>
<td>Approved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adult Still disease</td>
<td>Phase II; 2009–2011</td>
<td>NCT01002781</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Graves ophthalmopathy</td>
<td>Phase III; 2011–2013</td>
<td>NCT01027699</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Relapsing polyarthritis</td>
<td>Phase II; 2010–2012</td>
<td>NCT01104480</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ankylosing spondylitis</td>
<td>Phase III; 2010–2014</td>
<td>NCT01209702</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Type II diabetes and exercise</td>
<td>2010–2012</td>
<td>NCT01073826</td>
</tr>
<tr>
<td></td>
<td><strong>REGN88 (SAR153191)</strong></td>
<td>Regeneron/ Sanofi-Aventis</td>
<td>Fully human IL-6R–specific mAb</td>
<td>Rheumatoid arthritis</td>
<td>Phase II; 2010–2012</td>
<td>NCT01217814</td>
</tr>
<tr>
<td></td>
<td><strong>ALX-0061</strong></td>
<td>Abylnx</td>
<td>IL-6R–specific nanobody</td>
<td>Rheumatoid arthritis</td>
<td>Phase I + II; 2011–2012</td>
<td>NCT01242488</td>
</tr>
<tr>
<td><strong>Global IL-6 blockade</strong></td>
<td><strong>CDP6038 (Olokizumab)</strong></td>
<td>UCB Inc.</td>
<td>IL-6–specific mAb</td>
<td>Rheumatoid arthritis</td>
<td>Phase I + II; 2009–2010</td>
<td>NCT01009242</td>
</tr>
<tr>
<td></td>
<td><strong>CNTO136 (Sirukumab)</strong></td>
<td>Centocor Inc.</td>
<td>Fully human IL-6–specific mAb</td>
<td>Rheumatoid arthritis</td>
<td>Phase II; 2008–2011</td>
<td>NCT00718718</td>
</tr>
<tr>
<td></td>
<td><strong>CNTO328 (sCLB, Siltuximab)</strong></td>
<td>Centocor Inc.</td>
<td>Chimeric IL-6–specific mAb</td>
<td>Castleman disease</td>
<td>Phase II; 2010–2012</td>
<td>NCT01024036</td>
</tr>
<tr>
<td></td>
<td><strong>CNTO136 (Sirukumab)</strong></td>
<td>Centocor Inc.</td>
<td>Fully human IL-6–specific mAb</td>
<td>Rheumatoid arthritis</td>
<td>Phase II; 2008–2011</td>
<td>NCT00718718</td>
</tr>
<tr>
<td></td>
<td><strong>CNTO328 (sCLB, Siltuximab)</strong></td>
<td>Centocor Inc.</td>
<td>Chimeric IL-6–specific mAb</td>
<td>Castleman disease</td>
<td>Phase II; 2008–2011</td>
<td>NCT00718718</td>
</tr>
<tr>
<td></td>
<td><strong>ALD518 (BMS-945429)</strong></td>
<td>Alder Biopharmaceuticals/ Bristol-Myers Squibb</td>
<td>Humanized IL-6–specific mAb, aglycosylated</td>
<td>Rheumatoid arthritis</td>
<td>Phase II; 2008–2009</td>
<td>NCT00867516</td>
</tr>
<tr>
<td></td>
<td><strong>C326</strong></td>
<td>Avidia</td>
<td>Anti–IL-6/anti–Fc avimer protein</td>
<td>Non–small cell lung cancer–related fatigue and cachexia</td>
<td>Phase II; 2008–2009</td>
<td>NCT00866970</td>
</tr>
<tr>
<td><strong>Selective IL-6 blockade</strong></td>
<td><strong>FE301</strong></td>
<td>Conaris/Ferring</td>
<td>Soluble gp130-Fc fusion protein</td>
<td>Crohn disease</td>
<td>Phase I; 2006–2007</td>
<td>NCT00353756</td>
</tr>
</tbody>
</table>

tion that intestinal epithelial cells express membrane-bound IL-6R (80) and that IL-6 signaling and STAT3 activation in these cells drives epithelial regeneration (102). When IL-6 trans-signaling is blocked by sgp130Fc, free IL-6 is not neutralized and directly stimulates STAT3 in intestinal epithelial cells via classical IL-6R signaling, leading to regeneration of the epithelium (102, 103). In light of this, it is interesting to note that tocilizumab is not recommended for patients with a preexisting history of diverticulitis. Although these are rare occurrences and tocilizumab displays a robust safety profile (1, 66), it will be important to better understand how IL-6 influences homeostatic processes, such as neutropenia, changes in cholesterol, and weight gain, which have been linked with tocilizumab intervention (2).

Future perspectives
Remission of disease and prevention of irreversible tissue damage remains the ultimate objective for treatment of inflammatory conditions like rheumatoid arthritis. To achieve this goal it is evident that appropriate early intervention is the most effective therapeutic strategy (124). However, clinical criteria alone are often inadequate to identify patients with rapidly progressing disease or predict the likely course of an inflammatory condition (124). As newer alternative biologics and small molecule inhibitors become clinically available, selecting the most appropriate treatment for an individual patient becomes more complex. So how do we improve clinical decisions on the best choice of drug for an individual patient becomes more complex. So how do we improve clinical decisions on the best choice of drug for an individual patient? In the context of IL-6 biology, we need to understand how gp130 signaling in acute resolving inflammation becomes distorted to instead drive chronic disease. The regulation of STAT3 by IL-6 has received considerable attention in the study of both cancer biology and (auto)immunity, and pathway signatures that reflect altered STAT3 activity have prognostic value in certain cancers (4, 110–112). Furthermore, pharmacogenomic approaches have identified genetic links between STAT3 and chronic disease. For example, meta-analysis of a genome-wide association study of a European patient cohort identified seven new rheumatoid arthritis risk loci. These included gene products associated with STAT3 signaling/activity (IL6ST [GP130], SPRED2, CCR6), while a further suggestive risk allele was noted in the IL6R gene (125). Future studies will, however, need to take a more integrated view to validate the functional impact of these risk loci. Ideally, this should include their impact on chronic disease progression and secondary outcomes associated with biologic interventions, such as plasma lipid profiles, infection incidence, mood, fatigue, and malignancy (2).

In summary, interventions directed against IL-6/gp130 signaling represent excellent targets for therapy. At present, the application of these drugs has been restricted to certain inflammatory conditions; however, as evidenced by the number of anti–IL-6 based modalities currently under clinical development (Table 1), this is likely to broaden over coming years. The emerging challenge is to know how best to target this inflammatory pathway and how to identify patients that may benefit most from IL-6–blocking therapies.

Acknowledgments
S. Rose-John and J. Scheller are funded by grants from the Deutsche Forschungsgemeinschaft, Bonn, Germany (SFB654, projects C5, C8; SFB841, project C1; SFB877, projects A1, A2) and by the Cluster of Excellence “Inflammation at Interfaces.” S.A. Jones is supported by grants from Arthritis Research UK (18286, 19381) and The Wellcome Trust and through an Arthritis Research UK Centre grant (18461) in Biomechanics and Bioengineering.

Address correspondence to: Stefan Rose-John, Institute of Biochemistry, Christian-Albrechts-University, Olshausenstrasse 40, D-24098 Kiel, Germany. Phone: 49.431.880.3336; Fax: 49.431.880.5007; E-mail: rosejohn@biochem.uni-kiel.de.


